Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Update

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the recipient of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 3,889 shares, an increase of 193.1% from the May 14th total of 1,327 shares. Approximately 2.3% of the shares of the stock are short sold. Based on an average daily volume of 1,517 shares, the short-interest ratio is presently 2.6 days.

Amplify Weight Loss Drug & Treatment ETF Stock Up 2.3%

Shares of THNR opened at $24.53 on Friday. The stock has a market cap of $4.17 million, a price-to-earnings ratio of 24.31 and a beta of 0.40. Amplify Weight Loss Drug & Treatment ETF has a 12 month low of $21.70 and a 12 month high of $27.28. The company has a 50-day moving average price of $24.56 and a two-hundred day moving average price of $25.18.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC grew its position in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,891 shares of the company’s stock after acquiring an additional 1,215 shares during the period. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent reporting period.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.